Copyright
©The Author(s) 2021.
World J Gastroenterol. Nov 14, 2021; 27(42): 7210-7232
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7210
Published online Nov 14, 2021. doi: 10.3748/wjg.v27.i42.7210
Phage | Experiment | Finding | Ref. |
phiCD140 | A single dose of phage treatment for C. difficile infection in hamsters | Surviving of phage treated hamster | [135] |
phiCD27 | Phage treatment of CDI in an in vitro batch fermentation and human colon model | (1) Reduction of both vegetative cell and toxin A and toxin B productions from C. difficile; and (2) No impact on others gut microbes | [135] |
phiCDHM1 to phiCDHM6, and phiCDHS1 | (1) Investigation for an effective phage combination; and (2) Phage delivered orally in hamster model every 8 h after C. difficile challenge | (1) Discovery of phage-resistant colonies after a single phage treatment; and (2) Reduction of C. difficile amount and colonization using phage combination in vivo | [124] |
phiCDHM1, 2, 5, and 6 | (1) Phage treatment before and after the biofilm formation; (2) First time using Galleria mellonella (wax moth) model for C. difficile phage; and (3) Using phage in combination with antibiotics (vancomycin) | (1) Reduction and prevention of the biofilm establishment in vitro; and (2) Disease prevention in the prophylaxis group and increasing the wax moth survival rates | [130] |
phiCDHM1, 2, 5, and 6 | (1) Optimized temperate phage cocktail to treat in batch fermentation model; and (2) First metagenomic analysis of phage treatment on gut microbiome | (1) C. difficile elimination after 24 h in prophylactic condition while maintain other microbiota components; and (2) No significant impact on other bacterial groups in human gut | [127] |
phiCDHS1 | Measurement of planktonic and adhered C. difficile cells and free phage to human colon tumorigenic cell line HT-29 | (1) Reduction of planktonic and adhered C. difficile; and (2) No cytotoxicity to human cells | [129] |
phiCD24-2 | (1) Using engineered phage delivered Type 1-B CRISPR system as antimicrobial agent in vitro and in vivo; and (2) Mutation of phage lysogenic gene by the cI repressor and integrase gene deletion | (1) C. difficile eradication effectively in engineered phage comparing with wild-type phage; and (2) Detection of lysogen due to potentially functional complements from C. difficile prophage | [125] |
- Citation: Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232
- URL: https://www.wjgnet.com/1007-9327/full/v27/i42/7210.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i42.7210